{
  "id": "58dbbdac8acda3452900001e",
  "type": "yesno",
  "question": "Is hydroxyurea usually used to treated infectious disease?",
  "ideal_answer": "Hydroxyurea represents the only available disease-modifying therapy for Sickle Cell Anemia (SCA).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/21196716",
    "http://www.ncbi.nlm.nih.gov/pubmed/26275071",
    "http://www.ncbi.nlm.nih.gov/pubmed/27677923",
    "http://www.ncbi.nlm.nih.gov/pubmed/15307105",
    "http://www.ncbi.nlm.nih.gov/pubmed/20008183"
  ],
  "snippets": [
    {
      "text": "Hydroxyurea represents the only available disease-modifying therapy for SCA, and has proven safety and efficacy in high-resource countries",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275071",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In conclusion, the data here presented suggests that hydroxyurea may prevent priapism attacks in sickle cell disease, probably at higher doses than usually prescribed for painful crisis prevention..",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15307105",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical follow-up of hydroxyurea-treated adults with sickle cell disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21196716",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "t may also attenuate optimal response to hydroxyurea therapy, the only effective and practical treatment option for SCD in sub-Saharan Africa",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27677923",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Hydroxyurea is one of the most successfully used therapies for sickle cell disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15307105",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical experience with hydroxyurea for patients with sickle cell disease (SCD) has been accumulating for the past 25 years. The bulk of the current evidence suggests that hydroxyurea is well-tolerated, safe, and efficacious for most patients with SCD",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20008183",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.disease-ontology.org/api/metadata/DOID:10923",
    "http://www.biosemantics.org/jochem#4275774",
    "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4275774",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000755",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006450",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006918"
  ],
  "exact_answer": "Yes"
}